PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
+16.7%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$2.44B
AUM Growth
+$2.44B
(+29%)
Cap. Flow
+$281M
Cap. Flow
% of AUM
11.54%
Top 10 Holdings %
Top 10 Hldgs %
36.96%
Holding
98
New
23
Increased
18
Reduced
15
Closed
20
Top Buys
| 1 |
Universal Health Services
UHS
|
$60.8M |
| 2 |
Eli Lilly
LLY
|
$59.2M |
| 3 |
McKesson
MCK
|
$53.7M |
| 4 |
AbbVie
ABBV
|
$45.5M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$44.8M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$114M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$33.8M |
| 3 |
XYZ
Block, Inc.
XYZ
|
$29.5M |
| 4 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$23.8M |
| 5 |
Microsoft
MSFT
|
$20M |
Sector Composition
| 1 | Healthcare | 92.27% |
| 2 | Financials | 0.44% |
| 3 | Consumer Discretionary | 0% |
| 4 | Industrials | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $153M | 5.39% | 981,131 +277,314 | +39% | +$43.3M |
|
2
Outset Medical
OM
$247M
| $151M | 5.3% | 2,911,207 +38,217 | +1% | +$1.98M |
|
|
3
AbbVie
ABBV
$372B
| $99.3M | 3.49% | 926,823 +425,073 | +85% | +$45.5M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $97.2M | 3.42% | 1,328,803 -30,617 | -2% | -$2.24M |
|
5
Arcus Biosciences
RCUS
$1.13B
| $87.6M | 3.08% | 3,373,460 +836,528 | +33% | +$21.7M |
|
|
6
Acadia Pharmaceuticals
ACAD
$4.38B
| $67.3M | 2.37% | 1,259,474 +838,387 | +199% | +$44.8M |
|
7
IQVIA
IQV
$32.4B
| $66.9M | 2.35% | 373,301 +35,314 | +10% | +$6.33M |
|
|
8
Universal Health Services
UHS
$11.6B
| $60.8M | 2.14% | +442,044 | New | +$60.8M |
|
|
9
Eli Lilly
LLY
$657B
| $59.2M | 2.08% | +350,645 | New | +$59.2M |
|
10
Avantor
AVTR
$9.18B
| $58.4M | 2.05% | 2,074,259 +804,189 | +63% | +$22.6M |
|
11
ICU Medical
ICUI
$3.15B
| $57.4M | 2.02% | 267,817 -35,182 | -12% | -$7.55M |
|
12
Gilead Sciences
GILD
$140B
| $54.9M | 1.93% | 941,674 -136,415 | -13% | -$7.95M |
|
13
AstraZeneca
AZN
$248B
| $54.7M | 1.92% | 1,094,600 +706,700 | +182% | +$35.3M |
|
|
NVRO
14
DELISTED
NEVRO CORP.
NVRO
| $54M | 1.9% | 311,940 -6,292 | -2% | -$1.09M |
|
|
15
McKesson
MCK
$85.4B
| $53.7M | 1.89% | +308,987 | New | +$53.7M |
|
16
Elevance Health
ELV
$71.8B
| $52.7M | 1.86% | 164,238 +60,783 | +59% | +$19.5M |
|
17
HCA Healthcare
HCA
$94.5B
| $51.6M | 1.81% | 313,487 -51,453 | -14% | -$8.46M |
|
|
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $45.9M | 1.61% | 209,006 -40,062 | -16% | -$8.8M |
|
19
Edwards Lifesciences
EW
$47.8B
| $44.5M | 1.57% | 487,842 | – | – |
|
20
Heron Therapeutics
HRTX
$207M
| $42.6M | 1.5% | 2,011,477 +139,465 | +7% | +$2.95M |
|
21
iRhythm Technologies
IRTC
$5.46B
| $40.6M | 1.43% | 171,028 +4,020 | +2% | +$954K |
|
22
Tenet Healthcare
THC
$16.3B
| $39.4M | 1.39% | 986,019 +144,825 | +17% | +$5.78M |
|
23
Danaher
DHR
$147B
| $38M | 1.34% | 171,252 +7,589 | +5% | +$1.69M |
|
24
UnitedHealth
UNH
$281B
| $35.8M | 1.26% | +102,099 | New | +$35.8M |
|
25
Penumbra
PEN
$10.6B
| $34.9M | 1.23% | 199,694 -39,703 | -17% | -$6.95M |
|